Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

ClinicalTrials.gov ID: NCT06467084

Public ClinicalTrials.gov record NCT06467084. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With Hereditary Angioedema Type I or II

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.

Study identification

NCT ID
NCT06467084
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Enrollment
36 participants

Conditions and interventions

Eligibility (public fields only)

Age range
2 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 1, 2024 (Actual)
Primary completion
Jan 15, 2026 (Actual)
Completion
Jan 15, 2026 (Actual)
Last update posted
Aug 5, 2026

2024 – 2026

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
KalVista Investigative Site Birmingham Alabama 35209 —
KalVista Investigative Site Scottsdale Arizona 85251 —
KalVista Investigative Site San Diego California 92123 —
KalVista Investigative Site Santa Monica California 90404 —
KalVista Investigative Site Evansville Indiana 47715 —
KalVista Investigative Site Wheaton Maryland 20902 —
KalVista Investigative Site St Louis Missouri 63141 —
KalVista Investigative Site Toledo Ohio 43560 —
KalVista Investigative Site Hershey Pennsylvania 17011 —
KalVista Investigative Site Dallas Texas 75231 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06467084, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 5, 2026 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06467084 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →